BC Cancer - Vancouver

600 W 10th Avenue
Vancouver, BC V5Z 4E6

Clinical Trial Unit Manager
Darko Curman
604-877-6000 x673226
dcurman@bccancer.bc.ca

Hematology

GO29781: An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Cancer Type
Hematology
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Cancer Type
Hematology
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

Cancer Type
Hematology
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Cancer Type
Hematology
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

ESCALADE: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects ≤65 Years With Previously Untreated Non-Germinal Center DLBCL

Cancer Type
Hematology
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

LY.18: A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Cancer Type
Hematology
Phase I
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase II Study of Acalabrutinib in Combination With R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Cancer Type
Hematology
Phase III
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom’s Macroglobulinemia

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma 

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov

A Multi-staged Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Cancer Type
Hematology
Phase II
Recruiting Dates
BC Cancer - Vancouver
Open Recruiting Date
View on ClinicalTrials.gov
Back to top